在患有持续牛奶蛋白过敏的儿童接受口服免疫治疗后的免疫特征
Miguel Ângelo-Dias1,2, Catarina Martins1,3, Susana Piedade4
1CHRC, NOVA Medical School (NMS), Faculdade de Ciências Médicas (FCM), Universidade NOVA de Lisboa, Lisboa, Portugal.
Allergy, asthma & immunology research
|January 27, 2026
概括
口服免疫疗法 (OIT) 帮助患有持续牛奶蛋白过敏 (CMPA) 的儿童通过调节免疫细胞和特定免疫球蛋白 (sIgs) 来实现耐受性. 经过OIT后的免疫恢复受到年龄和时间的影响,这表明复杂的耐受性机制.
科学领域:
- 免疫学 免疫学 免疫学
- 过敏研究 研究过敏
- 儿科医学 儿科医学
背景情况:
- 牛奶蛋白过敏 (CMPA) 是一种普遍存在的儿童食物过敏.
- 口服免疫疗法 (OIT) 是对持续性CMPA (pCMPA) 的有效治疗方法,但其免疫机制尚未完全理解.
研究的目的:
- 在成功完成OIT后,描述pCMPA儿童的免疫特征.
- 为了比较治疗儿童和健康对照组 (HC) 的免疫特征.
主要方法:
- 使用流式细胞计量来评估T和B细胞种群.
- 度酶免疫测试测量了对牛奶过敏原的特定免疫球蛋白 (sIgs).
- 研究包括30名pCMPA和33名HC儿童.
主要成果:
- 与HC相比,pCMPA后的OIT儿童显示B细胞减少和T细胞激活.
- 在OIT后,特定IgE (sIgE) 水平下降,而特定IgG4 (sIgG4) 增加.
- 免疫恢复因年龄而异;仅在10岁以上的儿童中观察到T细胞和B细胞的显著减少.
结论:
- OIT调节了pCMPA中的免疫激活,降低了sIgE,增加了sIgG4.
- 不同的SIG与免疫参数的关系不同,这表明它们的耐受能力不同.
- 年龄和OIT后的时间影响免疫恢复,突显了耐受性诱导的复杂性.
相关概念视频
Cross-reactivity
28.7K
Overview
28.7K
Allergic Reactions
26.4K
Overview
26.4K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
2.4K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.4K
Allergic Reactions: Anaphylaxis
280
Anaphylaxis is a severe, life-threatening hypersensitivity reaction mediated by Immunoglobulin E (IgE) antibodies. When IgE binds to allergens, it triggers the release of mediators– histamine, leukotrienes, and prostaglandins from mast cells and basophils. These mediators cause vasodilation, edema, and inflammation, leading to various symptoms.The primary allergens causing anaphylaxis include food items (e.g., peanuts, shellfish), drugs (e.g., penicillin, asparaginase, corticotropin,...
280
Hypersensitivity Reactions: Delayed Hypersensitivity Reactions
359
Delayed-Type Hypersensitivity (DTH), or Type IV hypersensitivity, is a cell-mediated immune response. It occurs when T cells, rather than antibodies, mediate a reaction to specific antigens. It is characterized by a delayed onset (1-2 days) and involves the recruitment of macrophages to the inflammation site.The initiation of a DTH response begins with the sensitization of T cells. During this phase, which lasts at least 1-2 weeks, antigen-specific T cells are activated, clonally expanded, and...
359
Hypersensitivity Reactions: Immune-Complex Reactions
269
Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum...
269


